Caladrius Biosciences Inc

NASDAQ:CLBS  
0.53
0.00 (-0.58%)
Products, Regulatory

Caladrius Biosciences Provides Update On Phase 2B Freedom Trial Of Xowna® In Coronary Microvascular Dysfunction

Published: 05/23/2022 20:31 GMT
Caladrius Biosciences Inc (CLBS) - Caladrius Biosciences Provides Update on Phase 2b Freedom Trial of Xowna® in Coronary Microvascular Dysfunction.
Caladrius Biosciences - Interim Analysis to Be Conducted Following Enrollment Suspension in Double-blind, Randomized, Placebo-controlled Clinical Trial.
Caladrius Biosciences Inc - Next Development Steps for Xowna to Be Announced by Year-end 2022 Following Regulatory and Business Review.
Caladrius Biosciences Inc - Suspended Patient Enrollment in Its Phase 2b Study of Xowna.
Caladrius Biosciences Inc - Believes Revised Timeline for Freedom Trial is Not Viable for Financial and Commercial Reasons.